<DOC>
	<DOC>NCT01520831</DOC>
	<brief_summary>This trial is conducted in Europe. The aim of this trial is to demonstrate a difference between the pharmacodynamics and pharmacokinetics of biphasic insulin aspart 30, biphasic insulin aspart 50, biphasic insulin aspart 70 and insulin aspart in healthy subjects.</brief_summary>
	<brief_title>Comparison of Biphasic Insulin Aspart (30, 50 and 70) and Insulin Aspart in Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Insulin, Globin Zinc</mesh_term>
	<mesh_term>Insulin degludec, insulin aspart drug combination</mesh_term>
	<mesh_term>Insulin aspart, insulin aspart protamine drug combination 30:70</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Biphasic Insulins</mesh_term>
	<mesh_term>Insulin Aspart</mesh_term>
	<mesh_term>Insulin, Long-Acting</mesh_term>
	<mesh_term>Insulin, Isophane</mesh_term>
	<criteria>Body mass index between 18 and 28 kg/m^2 inclusive HbA1c within the normal laboratory range Non smoker for at least three months Females of childbearing potential using acceptable methods of contraception, including tubal ligation, an intrauterine device (IUD) , the oral contraceptive pill or barrier methods Subjects who have received any investigational drug in the 3 months prior to the start of dosing Any disease requiring regular use of non topical prescription medicines Any serious systemic infectious disease that occurred in the 4 weeks prior to the first dose of test drug Any intercurrent illness or endocrine disorders that may affect blood glucose Subject with a history of drug or alcohol dependence Subject with a first degree relative with diabetes mellitus Subject with a history of clinically relevant allergic reactions to medical products Subjects who have donated any blood or plasma in the past 3 month preceding screening</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>